文献速递药物相互作用特殊人群用药

日本健康志愿者中CYP450底物司来帕格与氯吡格雷药物相互作用临床评价

Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers.
PubMed 文献 · Br J Clin Pharmacol · 2020-11-16

本研究在14名健康日本志愿者中探讨氯吡格雷对司来帕格及其活性代谢物ACT-333679药代动力学的影响。结果显示氯吡格雷不影响司来帕格本身暴露,但使ACT-333679的AUC0-∞增加约1.90倍;停药1天后抑制效应仍持续。提示日本临床合用司来帕格与氯吡格雷需谨慎,考虑剂量调整或减少给药频率。

要点

  • 氯吡格雷使ACT-333679的AUC0-∞增加约1.90倍(90%CI 1.69-2.14),对司来帕格本身无影响。
  • 氯吡格雷停药1天后对CYP2C8的抑制效应仍持续,ACT-333679的AUC0-∞增加1.37倍。
  • 日本临床合用司来帕格与氯吡格雷时应谨慎,考虑剂量调整或减少给药频率。

核心结论

  • 氯吡格雷显著增加司来帕格活性代谢物ACT-333679的暴露,提示日本临床合用时应谨慎并考虑剂量调整或减少给药频率。

研究设计与样本

  • 在14名健康日本志愿者中开展的药物相互作用研究,评估氯吡格雷对司来帕格及ACT-333679药代动力学的影响。

主要发现

  • 合用氯吡格雷不影响司来帕格的Cmax和AUC0-∞。
  • 合用氯吡格雷使ACT-333679的AUC0-∞增加约1.90倍(90%CI 1.69-2.14),Cmax无变化。
  • 氯吡格雷停药1天后给药,ACT-333679的AUC0-∞增加1.37倍(90%CI 0.93-2.02),提示抑制效应至少持续1天。

关键数值与推荐

  • 氯吡格雷使ACT-333679的AUC0-∞增加约1.90倍(90%CI 1.69-2.14)。
  • 氯吡格雷停药1天后ACT-333679的AUC0-∞增加1.37倍(90%CI 0.93-2.02)。

临床怎么用

  • 日本患者合用司来帕格与氯吡格雷时,应警惕ACT-333679暴露增加,考虑剂量调整或减少给药频率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The strong cytochrome P450 (CYP) 2C8 inhibitor gemfibrozil has been demonstrated to increase the area under the plasma concentration-time curve from 0 to infinity (AUC0-∞ ) of ACT-333679, an active metabolite of selexipag, by 11-fold. Similarly to gemfibrozil, the CYP2C8 inhibitor clopidogrel increased ACT-333679 concentration by 1.9-fold after a single loading dose (300 mg once daily) and 2.7-fold after repeated treatment with the maintenance dose (75 mg once daily) in Europeans. However, the effects of clopidogrel on the pharmacokinetics of selexipag and ACT-333679 have not been fully elucidated in the Japanese population. METHODS: We investigated the effect of clopidogrel on the pharmacokinetics of selexipag and ACT-333679 in 14 healthy Japanese volunteers. RESULTS: The concomitant administration of clopidogrel with selexipag did not influence the maximum concentration and AUC0-∞ of selexipag, whereas it significantly increased AUC0-∞ of ACT-333679 by approximately 1.90-fold (90% confidence interval 1.69-2.14) without changing the maximum concentration. When selexipag was administered 1 day after clopidogrel was discontinued, the increase in AUC0-∞ of ACT-333679 was 1.37-fold (90% confidence interval 0.93-2.02), suggesting that, although the inhibitory effect of clopidogrel on CYP2C8 was reduced, it persisted for at least 1 day after withdrawal. CONCLUSION: Our results demonstrated the impact of clopidogrel on the pharmacokinetics of selexipag and its active metabolite and suggested that selexipag should be carefully prescribed with clopidogrel with dose adjustment or reducing the dosing frequency in Japanese clinical settings.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Katayama N, Odagiri K, Hakamata A, et al. Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers. Br J Clin Pharmacol. 2020. PMID: 32997809. doi:10.1111/bcp.14579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。